Clinical trial
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable…
NCT00074321 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00074321 |
|---|---|
| Title | Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors |
| Official title | A Phase I And Pharmacogenetic Study Of CPT-11, Oxaliplatin, And Capecitabine In Patients With Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | irinotecan hydrochloride, oxaliplatin, capecitabine, laboratory biomarker analysis, pharmacological study |
| Enrollment | 84 |
| Start date | Nov 1, 2003 |
| Primary completion | Jul 1, 2010 |
| First posted | Dec 11, 2003 |
| Last update posted | Jun 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: